The estimated Net Worth of Laura Damme is at least $682 mil dollars as of 14 December 2022. Ms. Damme owns over 10,937 units of TransMedics stock worth over $681,659 and over the last 5 years she sold TMDX stock worth over $0. In addition, she makes $0 as Vice President - Clinical Affairs at TransMedics.
Laura has made over 1 trades of the TransMedics stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 10,937 units of TMDX stock worth $420,637 on 14 December 2022.
The largest trade she's ever made was exercising 10,937 units of TransMedics stock on 14 December 2022 worth over $420,637. On average, Laura trades about 1,823 units every 0 days since 2019. As of 14 December 2022 she still owns at least 4,740 units of TransMedics stock.
You can see the complete history of Ms. Damme stock trades at the bottom of the page.
Laura Damme serves as Vice President - Clinical Affairs of the Company. Ms. Damme served as Director of Clinical Studies in both the United States and EMEA for Abbott (formerly Thoratec Corporation) since 1997.
Laura Damme is 56, she's been the Vice President - Clinical Affairs of TransMedics since 2019. There are 5 older and 9 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
Laura's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein, eJames R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: